Comparative Pharmacology
Head-to-head clinical analysis: ORAGRAFIN CALCIUM versus RENOGRAFIN 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORAGRAFIN CALCIUM versus RENOGRAFIN 60.
ORAGRAFIN CALCIUM vs RENOGRAFIN-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oragrafin Calcium is a diagnostic radiocontrast agent that contains calcium ipodate. It acts by absorbing X-rays due to its high iodine content (61% iodine by weight). After oral administration, it is absorbed and excreted into the bile, allowing radiographic visualization of the gallbladder and biliary ducts. It may also enhance CT imaging of the liver and biliary tree.
RENOGRAFIN-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality, iodinated contrast agent. It enhances radiographic contrast by absorbing X-rays due to the high atomic number of iodine. It distributes into the intravascular space and is excreted primarily by the kidneys via glomerular filtration without significant tubular reabsorption or secretion.
Oral: 5 mL (1 packet) orally, may repeat in 30-60 minutes if needed. Maximum 2 doses per procedure. Rectal: 100-200 mL of a 1:1 dilution with water as a retention enema.
Intravenous: 50-100 mL of a 60% solution as a single dose for CT or angiography. Intra-arterial: 5-50 mL depending on vessel size. Maximum total dose: 3 mL/kg.
None Documented
None Documented
Terminal elimination half-life is 1.2 hours (0.7–2.0 hours) in patients with normal renal function. May be prolonged in renal impairment (up to 18 hours in severe impairment).
Terminal elimination half-life: 1-2 hours in normal renal function. Prolonged in renal impairment: up to 50 hours. Clinically significant for timing of contrast imaging and risk of contrast-induced nephropathy.
Primarily renal: 90% of absorbed dose excreted unchanged in urine within 24 hours; <10% via feces. Biliary excretion is negligible in the absence of hepatobiliary obstruction.
Renal: 95-100% (glomerular filtration, no tubular reabsorption). Biliary/Fecal: negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent